BOLT Rasio cepet Bolt Biotherapeutics Inc.

The market price of Bolt Biotherapeutics (BOLT), as confirmed by the chart, is fixed at 2.66. However, global political tensions are hindering international medical trials and complicating the transportation of biomaterials, which delays the release of new drugs. Bolt Biotherapeutics (BOLT) aims to expand its oncology portfolio via ISAC technology, while the business remains resilient to economic crises, relying on the success of clinical phases and commercial potential.

The high macro-resilience of Bolt Biotherapeutics (BOLT) is driven by its focus on immuno-oncology, where success depends on clinical trials rather than market cycles. By analyzing the quick ratio, an investor can see the company's ability to cover short-term debts solely through cash and accounts receivable, excluding inventory, which confirms the issuer's financial autonomy and investment reliability.